Jennifer Turner, MD
Endocrinology, Diabetes & Metabolism · Morgantown, WVNPI 1760878623
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 296 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,251, 7.0 times the $320 reported in 2019.
Across 296 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$1K
- Lilly USA, LLC$441
- Xeris Pharmaceuticals, Inc.$419
- Abbott$362
- Corcept Therapeutics$276
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,464100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 80 | $1,309 |
| Amgen(2 entities) | 29 | $1,029 |
| Lilly USA, LLC | 22 | $441 |
| Xeris Pharmaceuticals, Inc. | 21 | $419 |
| Abbott | 22 | $362 |
| Corcept Therapeutics | 7 | $276 |
| Medtronic(2 entities) | 12 | $266 |
| AstraZeneca(2 entities) | 9 | $266 |
| Boehringer Ingelheim | 15 | $251 |
| Johnson & Johnson | 2 | $226 |
| Insulet Corporation | 9 | $173 |
| AbbVie | 8 | $164 |
| Dexcom, Inc. | 9 | $163 |
| Novartis | 8 | $158 |
| Sanofi-aventis U.S. LLC | 7 | $118 |
| Recordati_rare_diseases_inc. | 5 | $109 |
| Cequr Corporation | 3 | $102 |
| Ascendis Pharma Endocrinology Inc | 4 | $91 |
| Bayer | 2 | $80 |
| IBSA Pharma Inc. | 3 | $70 |
| Tandem Diabetes Care, Inc. | 3 | $64 |
| Pfizer | 3 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Rhythm Pharmaceuticals, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Alvogen Inc | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $19 |
| GSK | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,488 in reported general payments places this provider in the 75th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $225,759 |
| MounjaroTirzepatide | 79 | $112,127 |
| JardianceEmpagliflozin | 63 | $94,417 |
| TrulicityDulaglutide | 59 | $76,019 |
| Teriparatide | 16 | $39,488 |
| FarxigaDapagliflozin Propanediol | 25 | $35,263 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $32,427 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $24,492 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $20,295 |
| TradjentaLinagliptin | 19 | $15,773 |
| Gvoke Hypopen 2-PackGlucagon | 25 | $14,809 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $11,671 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,423 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $10,205 |
| Cinacalcet Hcl | 37 | $9,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,309 | $225,759156 claims |
| Lilly USA, LLCMounjaro, Trulicity | $441 | $188,146138 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $251 | $130,48696 claims |
| Alvogen IncTeriparatide | $23 | $39,48816 claims |
| AstraZenecaFarxiga | $266 | $35,26325 claims |
| AbbVieSynthroid | $164 | $5,62542 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $2,572192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Morgantown
- Jessica PeriniMorgantown$10K
- Adnan HaiderMorgantown$3K
- Jennifer GiordanoMorgantown$2K
- Nadia BarghouthiMorgantown$1K
- Apoorva IyerMorgantown$1K
- Jeffrey Zen-Ji RicoMorgantown$1K
- Tariq LatifMorgantown$844
- Mehjabeen SadiqMorgantown$684
- Sarah FatimaMorgantown$292
- Ann-Marie BusickMorgantown$227
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.